Category Archives: Europe
By Pharm Exec | Published: October 29, 2014
The global non-hodgkin lymphoma (NHL) treatment market will increase in value from $5.6 billion in 2013 to $9.2 billion by 2020, according to GBI Research.
By Guest Blogger | Published: October 28, 2014
The 2014 Pharmaceutical Price Regulation Scheme (PPRS), the voluntary agreement to cover pricing of branded medicines supplied to the NHS in the UK, included provisions for member companies to pay back to the Department of Health (DH) if spend went over pre-agreed growth rates. That has translated into £150 million already for the first two […]
By Guest Blogger | Published: October 27, 2014
By Leela Barham. The Cancer Drugs Fund (CDF) is a particular English approach to deal with rejections by the National Institute for Health and Care Excellence (NICE) for new cancer medicines. It’s now worth £280million a year — still a drop in the ocean compared to the £5 billion or so spent on cancer by […]
By Pharm Exec | Published: October 23, 2014
The recent termination of AbbVie’s deal to acquire Shire has “jolted the industry out of its reverie” by becoming pharma’s first major casualty of new US tax inversion legislation, says research and consulting firm GlobalData.
By Marylyn Donahue | Published: October 17, 2014
The Baltic States with its appropriate population size, sufficient infrastructure, and experienced and motivated investigators, make it an attractive choice for a clinical trial. In this article, Doatas Grina, Indre Tutlyte and Auudius Sveikata, PhD, that ran in the February 2013 issue of Applied Clinical Trials, presents a persuasive case for the area’s present desirability as well as […]